Samumed unveils MOA for Wnt inhibitor OA therapy

Samumed LLC (San Diego, Calif.) reported preclinical data showing that its small molecule Wnt pathway inhibitor osteoarthritis therapy, SM04690, functions through

Read the full 217 word article

User Sign In